Real-World Study Demonstrates Beneficial Effects of Ajovy Treatment for Individuals with Episodic and Chronic Migraine Switching from Other Anti-CGRP Therapies

Analysis of interim results from the FINESSE study (EUPAS44606) demonstrated that 38.6% of migraine patients previously treated with other anti-calcitonin gene-related peptide (CGRP) pathway monoclonal antibodies (mAbs) experienced a 50% or greater reduction in monthly migraine days after switching to Ajovy (fremanezumab-vfrm; Teva Pharmaceuticals, Tel Aviv, Israel). These results were presented at the  American Academy of Neurology (AAN) 2024 Annual Meeting.

Subgroup analysis of the ongoing prospective, observational FINESSE study included 140 adults (47.6 ± 11.5 years, 84.7% female) with EM or CM who experienced poor effectiveness or tolerability with a prior anti-CGRP pathway mAb and switched to Ajovy. The primary endpoint was the proportion of patients reaching a 50% or greater reduction in average number of monthly migraine days during the 6-month period after the first dose of Ajovy. Secondary endpoints included monthly average number of migraine days, migraine disability, headache impact, and acute medication use.

• 38.6% of individuals (n=54) achieved a 50% or greater reduction in monthly migraine days over 6 months (44.3% in episodic migraine, 31.2% in chronic migraine).
• The average number of monthly migraine days decreased from 13.3 ± 6.42 at baseline to 7.2 ± 5.47 at month 6.
• Acute migraine medication use decreased from 9.5 ± 4.92 days per month to 5.0 ± 3.86 days per month.